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Abstract
The incidence of end-stage renal disease (ESRD) continues to vary substantially between the countries in Europe that con-
tribute data to the ERA-EDTA Registry. Differences can be attributed to socioeconomic factors and prophylaxis programs for
patients with chronic kidney disease (CKD) and may also express real differences in CKD incidence. Recently, age-adjusted
ESRD incidence has begun to fall in many countries, probably related to improved prophylaxis. However, absolute rates may
increase, partly due to socioeconomic advances in countries with a low gross domestic product and partly due to continuing
increases in the proportion of elderly patients. Prevalence rates are expected to continue to increase, mainly due to in-
creases in relative transplant prevalence, improved graft survival times and continuing improvements in both dialysis and
transplant patient survival. Overall treatment results continue to improve.
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Introduction
This issue contains details from the ERA-EDTA Registry’s an-
nual report for 2014 [1]. The registry and its contributing na-
tional and regional registries are to be congratulated for this
continuing work, particularly because the effort involved is to a
large extent voluntary. It has documented the evolution of
European renal end-stage renal disease (ESRD) epidemiology
since 1964, primarily through the publication of annual reports
[2–5] and reviews of epidemiological trends [6–11]. The first pub-
lication [12] described the treatment of 271 dialysis patients, but
already by the 1971 report [13], details of 9411 dialysis and renal
transplant patients from 24 countries were available, corres-
ponding to a prevalence of 22 patients/million population
(ppm)/year. Prevalence has continued to increase: 1980, 118;
1990, 224; 1999, 583 [14]; 2010, 741 [2] and now 924 ppm. Data are
available from 35 countries. Seven countries are currently not
contributing data, the most important being Germany and
Russia. Because the number and identities of contributing
countries changes over time, overall year-on-year comparisons
should be treated with caution.
The end of the ESRD epidemic?
It has been some years since renal replacement therapy (RRT) in-
cidence rates started to stabilize in Europe [8, 15, 16].
Developments in European epidemiology between 2001 and 2011
for countries supplying the ERA-EDTA Registry with individual
data have recently been reviewed [10, 11]. The most remarkable
finding was that, for the first time, incidence rates fell in most
countries reporting individual data, with an overall age-adjusted
decrease from 131 to 124 ppm between 2008 and 2011. However,
the unadjusted rate for Europe as a whole has continued to in-
crease slightly, from 124 ppm in 2010 [2] to 133 ppm in 2014,
mainly due to a continuing increase in the average age at RRT ini-
tiation from 61.0 to 64.6 years. Thus previous fears of a continuing
increase in incidence>140 ppm [17] have been allayed. In Finland,
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the present rate of 81 ppm (previously 93) is among the lowest in
Europe. In Denmark, the decrease has been most notable among
the elderly with, for example, an approximate halving of the inci-
dence since 2001 among 60–69 year olds, from 400 to 218 ppm [18],
associated with a concurrent large increase in antihypertensive
drug use, particularly drugs blocking the renin–angiotensin system
(RAS) [19]. Although the number of transplanted patients in
Denmark continues to increase, the number of dialysis patients
has fallen by 9% since 2008. Other countries with notable decreases
in incidence include Austria and Norway [10]. Similar changes have
been noted in the USA, albeit from a higher base: adjusted inci-
dence has fallen from 387 to 354 ppm, and for patients >74 years,
from 1,801 to 1,556 ppm [20]. Somewhat surprisingly, considering
the rising incidence of type 2 diabetes mellitus (DM) in Europe and
the USA [21], incidence rates of RRT for diabetic nephropathy have
stabilized in Europe at 32 ppm, and have actually fallen in the
USA from 175 to 156 ppm. These findings suggest that a well-
organized program for prophylactic treatment of chronic kidney
disease (CKD) can reduce the incidence of RRT and ultimately
prevalence. However, prevalence will generally continue to increase
for some time to come, with the actual exception of Finland, where
absolute prevalence is expected to remain stable [22]. There are
several causes: there is a lag time between changes in incidence
and subsequent changes in prevalence, some countries will con-
tinue to increase RRT acceptance rates due to social and economic
progress and background population age will continue to increase,
resulting in a greater difference between standardized and real inci-
dence rates. Finally, RRT survival continues to increase.
Improved survival
Treatment results have improved throughout the history of mod-
ern nephrology; this trend continues for all treatment modalities
and is substantial. Thus, compared with the 2001–2005 cohort [2],
the 2008–2012 cohort shows a decrease in adjusted RRT mortality
at 2 years from 21 to 16.2%, dialysis mortality from 24.0 to 18.9%,
transplant mortality (dead donor) from 4.3 to 3.2%, transplant
mortality (living donor) from 3.2 to 1.4%, graft loss (dead donor)
from 12.1 to 9.8% and graft loss (living donor) from 8.8 to 5.4%,
with the 2005–2009 cohort showing intermediate results. Renal
transplant has probably benefitted from improved immunosup-
pressive therapy and preoperative and postoperative care. The im-
provement in dialysis mortality is more surprising considering the
general paucity of therapeutic randomized trials with positive re-
sults [23–26], but may be due to a generally successful therapeutic
response to epidemiological studies: better control of hyperphos-
phatemia, hypercalcemia and hyperparathyroidism [27]; vitamin
D therapy [28]; blood pressure [29]; hydration [29, 30] and better
predialysis preparation [31].
The report also shows a continuing adjusted survival advan-
tage for peritoneal dialysis (PD) relative to hemodialysis (HD) for
the first 4 years of therapy. This phenomenon has been
described many times before [32] and is independent of
preexisting comorbidity and predialysis planning [33]. The dif-
ference seems to be increasing [11, 33]. It may be causal; pos-
sible factors include better preservation of residual renal
function [34], the continuous nature of PD [35] and reduced
intradialytic side effects [36].
Differences in RRT incidence
One striking finding in the report is the large variation in inci-
dence between countries, ranging from 23 ppm in Ukraine to
237 ppm in Portugal. Among the ERA-EDTA Registry’s many ini-
tiatives, the EVEREST study [37] sought to identify factors deter-
mining the wide variation in RRT incidence throughout the
world. Gross domestic product (GDP) per capita, percentage of
GDP spent on health care, dialysis facility reimbursement rate
and private for-profit share of HD facilities were all found to be
important. Although there is little overall correlation between
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Fig. 1. Relationship of per capita GDP (International Monetary Fund 2015 figures) to RRT incidence in Europe in 2014. Incidence: unadjusted figures in patients/million
population (ppm)/year.
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RRT incidence and GDP per capita in Europe (Fig. 1), some
Eastern European countries with low GDP have low rates, sug-
gesting that socioeconomic factors still play a part in RRT ac-
ceptance rates. Previous studies have shown that economic
factors cease to be important once per capita GDP exceeds
US$20 000/year [38]. RRT incidence for most of these countries
is increasing and will probably continue to do so in the future.
Other factors of importance in determining the wide variation
in incidence are genetics [39, 40] birth weight [41], exercise [42],
DM prevalence, dietary habits [43] and prophylactic measures,
e.g., control of acidosis [44], hypertension (particularly by RAS
blockade) [45] and reduction of obesity [46] and tobacco con-
sumption [47, 48]. Middle income countries have generally high
rates (Fig. 1), suggesting that while access to RRT for these coun-
tries is not limited by economic factors, prophylactic programs
are not fully developed. The correlation between RRT due to dia-
betic nephropathy and overall RRT is virtually linear (Fig. 2):
50% of the difference in RRT incidence rates is accounted for
by differences in RRT due to diabetic nephropathy.
These observations suggest that the pattern of European
RRT incidence in the future will be complex, with some coun-
tries demonstrating a low but increasing incidence, others a sta-
ble pattern and others a, hopefully expanding, group showing
continuing reductions in adjusted incidence and eventually ab-
solute incidence.
Relative modality prevalence
Several factors influence the relative modality prevalence. Initial
modality choice, defined as the relative prevalence at 91 days after
RRT initiation is an important factor. Preemptive transplantation,
a highly desirable treatment, has increased from 3% in 2007 [11] to
5% in 2010 [2] to 6% now. Initial PD treatment has fallen from 15 to
13%, probably because many elderly patients are incapable of
home treatment and because assisted PD in the home is not
universally available. Second, transplantation activity will affect
transplant prevalence. The number of transplantations has
increased from 29 to 36 ppm since 2010 [2]. Third, since patient
mortality on dialysis is about three times higher than with trans-
plantation, the proportion of renal transplant patients will be ex-
pected to increase even in the absence of incidence changes. On
the other hand, since the number of elderly patients, who are
often unsuitable for transplantation, continues to increase, this
will tend to reduce relative transplant prevalence. Since 2010, the
relative prevalences of HD/PD/renal transplant has changed from
59/6/35 to 57/5/37%. An increase in the proportion of renal trans-
plant patients will lead to improved overall RRT survival even in
the absence of therapeutic improvements.
Conclusion
The importance of the ERA-EDTA Registry cannot be overempha-
sized. It is the world’s largest international registry, contributing
substantially to international comparisons. It forms the basis for
much health resource planning. In cooperation with the
European Society for Paediatric Nephrology, it is a valuable
source of epidemiological research, generating some 90 publica-
tions during the last 10 years. Under the umbrella organization of
the QUEST (Quality European STudies) initiative [17], interna-
tional research programs have been initiated, including the
EQUAL [49] and EVEREST [37, 50] studies. The registry’s main
handicap is incomplete data registration, in that only 17 of 35
countries are at present contributing detailed individual data.
This is a natural consequence of its voluntary nature. It is hoped
that an increasing recognition of the registry’s value and im-
provements in local organization will improve this figure.
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Fig. 2. Relationship of RRT incidence due to diabetes mellitus (DM) to overall unadjusted RRT in Europe in 2014. Incidence: unadjusted figures in patients/million popu-
lation (ppm)/year. Linear correlation: r ¼ 0.81, P<0.001.
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